In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
Mutual fund independent directors earned more in 2024 than in the year prior, and the pace at which their compensation grew was also higher year-on-year, according ...
The two longest-serving independent directors of ASA Gold and Precious Metals Ltd. have resigned from the board, and all litigation pursued by activist investor Saba Capital ...
Fund Board Views has refreshed and expanded its Editorial Think Tank ahead of its 10-year anniversary this fall. The nine members will continue to work closely with ...
The Securities and Exchange Commission last week dismissed charges against the defendants in the first-ever case related to enforcement of the liquidity risk management rule adopted ...